Lin CC - Search Results

1

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.

Cha TL, Wu TT, Vogelzang NJ, Huang CY, Huang SP, Lin CC, Ou YC, Pang ST, Shen DH, Wu WJ, Chang WY. Cha TL, et al. Among authors: lin cc. J Formos Med Assoc. 2017 Nov;116(11):825-836. doi: 10.1016/j.jfma.2017.04.005. Epub 2017 Oct 16. J Formos Med Assoc. 2017. PMID: 29046247 Free article. Review.

2

Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.

Hour TC, Huang CY, Lin CC, Chen J, Guan JY, Lee JM, Pu YS. Hour TC, et al. Among authors: lin cc. Anticancer Drugs. 2004 Sep;15(8):779-85. doi: 10.1097/00001813-200409000-00007. Anticancer Drugs. 2004. PMID: 15494640

3

Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.

Pu YS, Hsieh MW, Wang CW, Liu GY, Huang CY, Lin CC, Guan JY, Lin SR, Hour TC. Pu YS, et al. Among authors: lin cc, lin sr. Biochem Pharmacol. 2006 Mar 14;71(6):751-60. doi: 10.1016/j.bcp.2005.12.009. Epub 2006 Jan 18. Biochem Pharmacol. 2006. PMID: 16413505

4

Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.

Lin CC, Hsu CH, Huang CY, Cheng AL, Chen J, Vogelzang NJ, Pu YS. Lin CC, et al. Cancer. 2006 Mar 15;106(6):1269-75. doi: 10.1002/cncr.21738. Cancer. 2006. PMID: 16470604 Free article. Clinical Trial.

5

Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer.

Hour TC, Pu YS, Lin CC, Huang SW, Chen J, Chiu AW, Chen CJ, Huang CY. Hour TC, et al. Among authors: lin cc. Anticancer Res. 2006 Jan-Feb;26(1A):375-8. Anticancer Res. 2006. PMID: 16475721 Free article.

6

Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.

Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS. Lin CC, et al. J Urol. 2007 Jan;177(1):84-9; discussion 89. doi: 10.1016/j.juro.2006.08.058. J Urol. 2007. PMID: 17162009 Clinical Trial.

7

Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.

Lin CC, Hsu CH, Huang CY, Keng HY, Tsai YC, Huang KH, Cheng AL, Pu YS. Lin CC, et al. Anticancer Drugs. 2007 Apr;18(4):487-91. doi: 10.1097/CAD.0b013e3280126603. Anticancer Drugs. 2007. PMID: 17351402 Clinical Trial.

8

Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.

Lin CC, Hsu CH, Huang CY, Tsai YC, Huang KH, Cheng AL, Pu YS. Lin CC, et al. Urology. 2007 Mar;69(3):479-84. doi: 10.1016/j.urology.2006.12.010. Urology. 2007. PMID: 17382149 Clinical Trial.

9

Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.

Lin CC, Hsu CH, Hour TC, Cheng AL, Huang CY, Huang KH, Chen J, Pu YS. Lin CC, et al. Urol Oncol. 2007 May-Jun;25(3):207-13. doi: 10.1016/j.urolonc.2006.06.002. Urol Oncol. 2007. PMID: 17483017 Clinical Trial.

10

Systemic therapy for metastatic urothelial carcinoma.

Lin CC, Hsu CH, Pu YS, Vogelzang NJ. Lin CC, et al. BJU Int. 2008 Apr;101(7):795-803. doi: 10.1111/j.1464-410X.2007.07356.x. Epub 2007 Dec 5. BJU Int. 2008. PMID: 18070193 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,666 results

Search Page